Prognostic Factors and Survival Outcomes in Thyroid Cancer Patients With Bone Metastasis: Insights From a Population-Based Cohort Study
Authors' conclusion
This study highlights the critical role of age, pathological subtype, metastatic lesions, and radioisotope therapy in determining the prognosis of TCBM. These findings contribute to providing more rational treatment decisions and risk stratification for patients with TCBM.
Study context
- Population
- Patients with thyroid cancer with bone metastasis (TCBM), Surveillance, Epidemiology, and End Results (SEER) database, 2010–2021
- Participants
- 696 patients
- Outcome
- Prognostic factors for overall survival
Methodological detailsSEER database, univariable and multivariable Cox proportional hazards regression, Kaplan-Meier with log-rank tests
- SEER database
- Univariable and multivariable Cox proportional hazards regression
- Kaplan-Meier with log-rank tests
Main finding
As reported in the abstract
- Age ≥55 years: significantly reduced overall survival
- P < .001
- Anaplastic thyroid cancer (TC): significantly reduced overall survival
- P < .001
- Brain, liver and lung metastases: significantly reduced overall survival
- all P < .05
- T4 stage: significantly reduced overall survival
- P = .011
Observational data: associations, not effects.
Further findings
Significant factors for cancer-specific survival
- Anaplastic TC
- P < 0.001
- Liver metastases
- P = 0.010
- Lung metastases
- P < 0.001
- Radioisotope treatment
- P < 0.001
Original publication
Prognostic Factors and Survival Outcomes in Thyroid Cancer Patients With Bone Metastasis: Insights From a Population-Based Cohort Study. Endocr Pract. Published 16 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →